L
Lianxin Liu
Researcher at University of Science and Technology of China
Publications - 164
Citations - 6726
Lianxin Liu is an academic researcher from University of Science and Technology of China. The author has contributed to research in topics: Cancer & Internal medicine. The author has an hindex of 41, co-authored 144 publications receiving 4769 citations. Previous affiliations of Lianxin Liu include Peking Union Medical College & Chinese Ministry of Education.
Papers
More filters
Journal ArticleDOI
Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition).
Jian Zhou,Hui-Chuan Sun,Zheng Wang,Wen Ming Cong,Jian-Hua Wang,Meng Su Zeng,Jia Mei Yang,Ping Bie,Lianxin Liu,Tian Fu Wen,Guo Hong Han,Mao Qiang Wang,Rui Bao Liu,Li Gong Lu,Zheng Gang Ren,Minshan Chen,Zhao Chong Zeng,Ping Liang,Changhong Liang,Min Chen,Fu Hua Yan,Wen Ping Wang,Yuan Ji,Wen Wu Cheng,Chao Liu Dai,Wei-Dong Jia,Ya Ming Li,Ye Xiong Li,Jun Liang,Tian Shu Liu,Guo Yue Lv,Yi Lei Mao,Wei Xin Ren,Hong Cheng Shi,Wen Tao Wang,Xiaoying Wang,Bao Cai Xing,Jian Ming Xu,Jian Yong Yang,Ye Fa Yang,Sheng Long Ye,Zheng Yu Yin,Bo Heng Zhang,Shui Jun Zhang,Wei Ping Zhou,Ji Ye Zhu,Rong Liu,Ying Hong Shi,Yong Sheng Xiao,Zhi Dai,Gao Jun Teng,Jian Qiang Cai,Wei Lin Wang,Jia Hong Dong,Qiang Li,Feng Shen,Shu Kui Qin,Jia Fan +57 more
TL;DR: A guideline on the surveillance, diagnosis, staging, and treatment of HCC occurring in China is presented, and recommendations regarding patients with HCC in China are made to ensure optimum patient outcomes.
Journal ArticleDOI
Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition).
Jian Zhou,Hui-Chuan Sun,Zheng Wang,Wenming Cong,Jian-Hua Wang,Mengsu Zeng,Weiping Zhou,Ping Bie,Lianxin Liu,Tianfu Wen,Guohong Han,Maoqiang Wang,Ruibao Liu,Li Gong Lu,Zhengang Ren,Minshan Chen,Zhaochong Zeng,Ping Liang,Changhong Liang,Min Chen,Fuhua Yan,Wenping Wang,Yuan Ji,Jingping Yun,Dingfang Cai,Yongjun Chen,Wenwu Cheng,Shu-Qun Cheng,Chaoliu Dai,Wenzhi Guo,Baojin Hua,Xiaowu Huang,Wei-Dong Jia,Yaming Li,Yexiong Li,Jun Liang,Tianshu Liu,Guoyue Lv,Yilei Mao,Tao Peng,Wei Xin Ren,Hongcheng Shi,Guoming Shi,Kaishan Tao,Wentao Wang,Xiaoying Wang,Zhiming Wang,Bangde Xiang,Baocai Xing,Jian Ming Xu,Jiamei Yang,Jianyong Yang,Yefa Yang,Yunke Yang,Shenglong Ye,Zhengyu Yin,Bixiang Zhang,Boheng Zhang,Leida Zhang,Shuijun Zhang,Ti Zhang,Yongfu Zhao,Honggang Zheng,Jiye Zhu,Kangshun Zhu,Rong Liu,Yinghong Shi,Yongsheng Xiao,Zhi Dai,Gaojun Teng,Jianqiang Cai,Weilin Wang,Xiujun Cai,Qiang Li,Feng Shen,Shukui Qin,Jiahong Dong,Jia Fan +77 more
TL;DR: The new guidelines were endorsed and promulgated by the Bureau of Medical Administration of the National Health Commission of the People’s Republic of China in December 2019 and reflect the real-world situation in China regarding diagnosing and treating liver cancer in recent years.
Journal ArticleDOI
Tumour-associated mutant p53 drives the Warburg effect.
Cen Zhang,Juan Liu,Yingjian Liang,Rui Wu,Yuhan Zhao,Xuehui Hong,Meihua Lin,Haiyang Yu,Lianxin Liu,Arnold J. Levine,Wenwei Hu,Zhaohui Feng +11 more
TL;DR: It is shown that tumor-associatedmutp53 stimulates the Warburg effect in cultured cells and mutp53 knock-in mice as a new mutp 53 gain-of-function (GOF) and a mechanism for controlling the Warberg effect is revealed.
Journal ArticleDOI
Role of microRNA in anticancer drug resistance
TL;DR: Accumulating evidence is revealing an important role of miRNAs in anticancer drug resistance and miRNA expression profiling can be correlated with the development of antic cancer drug resistance.
Journal ArticleDOI
Hypoxia‐mediated sorafenib resistance can be overcome by EF24 through Von Hippel‐Lindau tumor suppressor‐dependent HIF‐1α inhibition in hepatocellular carcinoma
Yingjian Liang,Tongsen Zheng,Ruipeng Song,Jiabei Wang,Dalong Yin,Luoluo Wang,Haitao Liu,Lan-tian Tian,Xiang Fang,Xianzhi Meng,Hongchi Jiang,Jiaren Liu,Lianxin Liu +12 more
TL;DR: This study tested the hypothesis that hypoxia caused by the antiangiogenic effects of sustained sorafenib therapy could induce sorafinib resistance as a cytoprotective adaptive response, thereby limiting sorAFenib efficiency, and found that sustained SorafenIB therapy led to increased intratumor hypoxIA, which was associated with sorafanib sensitivity in HCC subcutaneous mice tumor models.